|Dr. Angelino is SVP of Pharmaceutical Sciences at bluebird bio. He manages the development, analytical development/QC, and clinical manufacturing functions for both our lentiviral vector materials and autologous drug products. He was most recently at Baxter Healthcare for which he led their Cambridge, MA R&D site.|
His experience spans the regulated environment from development through commercialization including lead roles on validation of Integrilin™, validation and commercial supply chain for generic enoxaparin (Lovenox™), and the ANDA submission for generic Copaxone™. He has worked on small-molecule, peptide, biologic, bioconjugate, oligonucleotide, and complex mixture development programs through various companies including Momenta Pharmaceuticals, Millennium Pharmaceuticals, and Bristol-Myers Squibb.
Mark holds a Ph.D. in Chemical Engineering from MIT.